Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | NRAS |
Variant | G115Efs*46 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | NRAS G115Efs*46 indicates a shift in the reading frame starting at amino acid 115 and terminating 46 residues downstream causing a premature truncation of the 189 amino acid Nras protein (UniProt.org). Due to the loss of the CAAX motif (PMID: 6087162, PMID: 21924373), G115Efs*46 is predicted to lead to a loss of Nras protein function resulting in inactivation of downstream signaling. |
Associated Drug Resistance | |
Category Variants Paths |
NRAS mutant NRAS exon4 NRAS G115Efs*46 NRAS mutant NRAS inact mut NRAS G115Efs*46 |
Transcript | NM_002524.5 |
gDNA | chr1:g.114709677delC |
cDNA | c.344delG |
Protein | p.G115Efs*46 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002524.4 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
NM_002524.5 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
NM_002524 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Cetuximab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |
NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Panitumumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |